spacer
home > ebr > winter 2003 > cordia-europabio convention 2003
PUBLICATIONS
European Biopharmaceutical Review

CORDIA-EuropaBio Convention 2003

Europe's first true biotechnology convention got off the ground in style in Vienna during the first week of December 2003. Approximately 1,300 delegates from 37 countries attended the Convention, which featured six plenary sessions, 60 conference panel sessions (across health care, industrial and agri-food biotechnology), six workshops, 10 different therapeutic/technology partnering sessions and an international exhibition with a range of companies from across the world.

The conference programme launched directly into the key issues that the European sector faces with the Opening Plenary featuring representation from all stakeholders in the future development of the European biotechnology industry - political, scientific, patient, mainstream industry and SMEs. The EU's Lisbon Summit objective to become the leading knowledge-based economy by 2010 is clearly not realisable on present performance. Even worse, the gap between Europe and North America is widening with Mrs Mary Harney, Deputy Prime Minister of Ireland and incoming President of the EU Competitiveness Council quoting that whilst the US is currently on average "30 per cent richer than Europe", it will be "50 per cent richer by the year 2050" if things continue as they are.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Review by Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement